Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients
Company leadership discussed key insights for patients with MELAS with clinician-researcher, Amel Karaa, M.D., and Philip Yeske, Ph.D. of UMDF
Read more at globenewswire.com